Publications by authors named "Obri Investigators"
Article Synopsis
- The study aimed to compare the retention rates of tumor necrosis factor inhibitors (TNFi) and tofacitinib (TOFA) for rheumatoid arthritis patients using combined data from two Canadian registries, addressing previous findings that were limited by small sample sizes.
- A total of 1,318 patients starting either TNFi (825) or TOFA (493) were analyzed, revealing similar overall discontinuation rates between the two groups; however, TNFi users were significantly less likely to discontinue treatment due to adverse events.
- The findings suggest that while discontinuation for any reason was comparable between TNFi and TOFA, TNFi had a better profile for patients regarding treatment-related side effects.
